Moleculin Biotech, Inc. - Common Stock (MBRX)
0.8020
-0.0336 (-4.02%)
NASDAQ · Last Trade: Jul 19th, 3:14 AM EDT

Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity
Via ACCESSWIRE · April 25, 2024

- Live video webcast presentations with participating companies -
Via ACCESSWIRE · January 11, 2023

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022. As part of the virtual
By JTC Team, LLC · Via AccessWire · January 12, 2022

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies - PITTSTOWN, NJ / ACCESSWIRE / November 4, 2021 / November 4, 2021 - JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor Roundtable Event November 16-18,
By JTC Team, LLC · Via AccessWire · November 4, 2021